| Year |
Citation |
Score |
| 2020 |
Shao H, Zhu Q, Lu H, Chang A, Gao C, Zhou Q, Luo K. HEXIM1 controls P-TEFb processing and regulates drug sensitivity in triple negative breast cancer. Molecular Biology of the Cell. mbcE19120704. PMID 32520633 DOI: 10.1091/Mbc.E19-12-0704 |
0.401 |
|
| 2020 |
Lu Y, Wu T, Gutman O, Lu H, Zhou Q, Henis YI, Luo K. Phase separation of TAZ compartmentalizes the transcription machinery to promote gene expression. Nature Cell Biology. PMID 32203417 DOI: 10.1038/S41556-020-0485-0 |
0.4 |
|
| 2020 |
Lu Y, Wu T, Zhu Q, Gutman O, Henis Y, Luo K. Abstract IA27: Regulation of Hippo and TAZ signaling in breast cancer Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Hippo19-Ia27 |
0.509 |
|
| 2018 |
Zhu Q, Chang A, Xu A, Luo K. The regulatory protein SnoN antagonizes Activin/Smad2 signaling and thereby promotes adipocytese differentiation and obesity in mice. The Journal of Biological Chemistry. PMID 30030373 DOI: 10.1074/Jbc.Ra118.003678 |
0.465 |
|
| 2016 |
Luo K. Signaling Cross Talk between TGF-β/Smad and Other Signaling Pathways. Cold Spring Harbor Perspectives in Biology. PMID 27836834 DOI: 10.1101/cshperspect.a022137 |
0.44 |
|
| 2016 |
Jiang L, He B, Pan D, Luo K, Yi Q, Gu Z. Anti-Cancer Efficacy of Paclitaxel Loaded in pH Triggered Liposomes. Journal of Biomedical Nanotechnology. 12: 79-90. PMID 27301174 |
0.407 |
|
| 2016 |
Zhu Q, Le Scolan E, Jahchan N, Ji X, Xu A, Luo K. SnoN Antagonizes the Hippo Kinase Complex to Promote TAZ Signaling during Breast Carcinogenesis. Developmental Cell. PMID 27237790 DOI: 10.1016/J.Devcel.2016.05.002 |
0.783 |
|
| 2016 |
Jiang L, Li L, He B, Pan D, Luo K, Yi Q, Gu Z. Anti-cancer efficacy of Paclitaxel loaded in pH triggered liposomes Journal of Biomedical Nanotechnology. 12: 79-90. DOI: 10.1166/jbn.2016.2123 |
0.36 |
|
| 2016 |
Guo C, Hu J, Bains A, Pan D, Luo K, Li N, Gu Z. The potential of peptide dendron functionalized and gadolinium loaded mesoporous silica nanoparticles as magnetic resonance imaging contrast agents Journal of Materials Chemistry B. 4: 2322-2331. DOI: 10.1039/c5tb02709h |
0.314 |
|
| 2015 |
She W, Pan D, Luo K, He B, Cheng G, Zhang C, Gu Z. PEGylated Dendrimer-Doxorubicin Cojugates as pH-Sensitive Drug Delivery Systems: Synthesis and In Vitro Characterization. Journal of Biomedical Nanotechnology. 11: 964-78. PMID 26353586 DOI: 10.1166/jbn.2015.1865 |
0.363 |
|
| 2015 |
Lu H, Xue Y, Yu GK, Arias C, Lin J, Fong S, Faure M, Weisburd B, Ji X, Mercier A, Sutton J, Luo K, Gao Z, Zhou Q. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism. Elife. 4. PMID 26083714 DOI: 10.7554/Elife.06535 |
0.39 |
|
| 2015 |
Rashidian J, Le Scolan E, Ji X, Zhu Q, Mulvihill MM, Nomura D, Luo K. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression. Science Signaling. 8: ra14. PMID 25670202 DOI: 10.1126/Scisignal.2005735 |
0.557 |
|
| 2015 |
Luo K, VanHook AM. Science signaling podcast: 10 February 2015 Science Signaling. 8. DOI: 10.1126/Scisignal.Aaa7572 |
0.312 |
|
| 2014 |
Pan D, She W, Guo C, Luo K, Yi Q, Gu Z. PEGylated dendritic diaminocyclohexyl-platinum (II) conjugates as pH-responsive drug delivery vehicles with enhanced tumor accumulation and antitumor efficacy. Biomaterials. 35: 10080-92. PMID 25263685 DOI: 10.1016/j.biomaterials.2014.09.006 |
0.387 |
|
| 2014 |
Li N, Li N, Yi Q, Luo K, Guo C, Pan D, Gu Z. Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent. Biomaterials. 35: 9529-45. PMID 25145854 DOI: 10.1016/j.biomaterials.2014.07.059 |
0.391 |
|
| 2014 |
Ji X, Lu H, Zhou Q, Luo K. LARP7 suppresses P-TEFb activity to inhibit breast cancer progression and metastasis. Elife. 3: e02907. PMID 25053741 DOI: 10.7554/Elife.02907 |
0.442 |
|
| 2014 |
Zhang C, Pan D, Luo K, She W, Guo C, Yang Y, Gu Z. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy. Advanced Healthcare Materials. 3: 1299-308. PMID 24706635 DOI: 10.1002/adhm.201300601 |
0.367 |
|
| 2014 |
Ji X, Lu H, Zhou Q, Luo K. Author response: LARP7 suppresses P-TEFb activity to inhibit breast cancer progression and metastasis Elife. DOI: 10.7554/Elife.02907.015 |
0.343 |
|
| 2013 |
Zhu Q, Kim YH, Wang D, Oh SP, Luo K. SnoN facilitates ALK1-Smad1/5 signaling during embryonic angiogenesis. The Journal of Cell Biology. 202: 937-50. PMID 24019535 DOI: 10.1083/Jcb.201208113 |
0.575 |
|
| 2013 |
Yang Y, Pan D, Luo K, Li L, Gu Z. Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy. Biomaterials. 34: 8430-43. PMID 23896006 DOI: 10.1016/j.biomaterials.2013.07.037 |
0.386 |
|
| 2013 |
Jahchan NS, Ouyang G, Luo K. Expression profiles of SnoN in normal and cancerous human tissues support its tumor suppressor role in human cancer. Plos One. 8: e55794. PMID 23418461 DOI: 10.1371/Journal.Pone.0055794 |
0.732 |
|
| 2012 |
Jahchan NS, Wang D, Bissell MJ, Luo K. SnoN regulates mammary gland alveologenesis and onset of lactation by promoting prolactin/Stat5 signaling. Development (Cambridge, England). 139: 3147-56. PMID 22833129 DOI: 10.1242/Dev.079616 |
0.778 |
|
| 2012 |
Pan D, Zhu Q, Conboy MJ, Conboy IM, Luo K. SnoN activates p53 directly to regulate aging and tumorigenesis. Aging Cell. 11: 902-11. PMID 22805162 DOI: 10.1111/J.1474-9726.2012.00857.X |
0.481 |
|
| 2011 |
Javelaud D, van Kempen L, Alexaki VI, Le Scolan E, Luo K, Mauviel A. Efficient TGF-β/SMAD signaling in human melanoma cells associated with high c-SKI/SnoN expression. Molecular Cancer. 10: 2. PMID 21211030 DOI: 10.1186/1476-4598-10-2 |
0.502 |
|
| 2010 |
Jahchan NS, Luo K. SnoN in mammalian development, function and diseases. Current Opinion in Pharmacology. 10: 670-5. PMID 20822955 DOI: 10.1016/J.Coph.2010.08.006 |
0.776 |
|
| 2010 |
Jahchan NS, You YH, Muller WJ, Luo K. Transforming growth factor-beta regulator SnoN modulates mammary gland branching morphogenesis, postlactational involution, and mammary tumorigenesis. Cancer Research. 70: 4204-13. PMID 20460516 DOI: 10.1158/0008-5472.Can-10-0135 |
0.804 |
|
| 2009 |
Pan D, Zhu Q, Luo K. SnoN functions as a tumour suppressor by inducing premature senescence. The Embo Journal. 28: 3500-13. PMID 19745809 DOI: 10.1038/emboj.2009.250 |
0.615 |
|
| 2009 |
Deheuninck J, Luo K. Ski and SnoN, potent negative regulators of TGF-beta signaling. Cell Research. 19: 47-57. PMID 19114989 DOI: 10.1038/cr.2008.324 |
0.463 |
|
| 2008 |
Le Scolan E, Zhu Q, Wang L, Bandyopadhyay A, Javelaud D, Mauviel A, Sun L, Luo K. Transforming growth factor-beta suppresses the ability of Ski to inhibit tumor metastasis by inducing its degradation. Cancer Research. 68: 3277-85. PMID 18451154 DOI: 10.1158/0008-5472.Can-07-6793 |
0.567 |
|
| 2008 |
He N, Jahchan NS, Hong E, Li Q, Bayfield MA, Maraia RJ, Luo K, Zhou Q. A La-related protein modulates 7SK snRNP integrity to suppress P-TEFb-dependent transcriptional elongation and tumorigenesis. Molecular Cell. 29: 588-99. PMID 18249148 DOI: 10.1016/J.Molcel.2008.01.003 |
0.73 |
|
| 2007 |
Tu AW, Luo K. Acetylation of Smad2 by the co-activator p300 regulates activin and transforming growth factor beta response. The Journal of Biological Chemistry. 282: 21187-96. PMID 17478422 DOI: 10.1074/Jbc.M700085200 |
0.83 |
|
| 2007 |
Wrighton KH, Liang M, Bryan B, Luo K, Liu M, Feng XH, Lin X. Transforming growth factor-beta-independent regulation of myogenesis by SnoN sumoylation. The Journal of Biological Chemistry. 282: 6517-24. PMID 17202138 DOI: 10.1074/Jbc.M610206200 |
0.533 |
|
| 2007 |
Zhu Q, Krakowski AR, Dunham EE, Wang L, Bandyopadhyay A, Berdeaux R, Martin GS, Sun L, Luo K. Dual role of SnoN in mammalian tumorigenesis. Molecular and Cellular Biology. 27: 324-39. PMID 17074815 DOI: 10.1128/Mcb.01394-06 |
0.753 |
|
| 2005 |
Zhu Q, Pearson-White S, Luo K. Requirement for the SnoN oncoprotein in transforming growth factor beta-induced oncogenic transformation of fibroblast cells. Molecular and Cellular Biology. 25: 10731-44. PMID 16314499 DOI: 10.1128/MCB.25.24.10731-10744.2005 |
0.569 |
|
| 2005 |
Krakowski AR, Laboureau J, Mauviel A, Bissell MJ, Luo K. Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-beta signaling by sequestration of the Smad proteins. Proceedings of the National Academy of Sciences of the United States of America. 102: 12437-42. PMID 16109768 DOI: 10.1073/Pnas.0504107102 |
0.78 |
|
| 2005 |
Pan D, Estévez-Salmerón LD, Stroschein SL, Zhu X, He J, Zhou S, Luo K. The integral inner nuclear membrane protein MAN1 physically interacts with the R-Smad proteins to repress signaling by the transforming growth factor-{beta} superfamily of cytokines. The Journal of Biological Chemistry. 280: 15992-6001. PMID 15647271 DOI: 10.1074/Jbc.M411234200 |
0.795 |
|
| 2004 |
Wang D, Park JS, Chu JS, Krakowski A, Luo K, Chen DJ, Li S. Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor beta1 stimulation. The Journal of Biological Chemistry. 279: 43725-34. PMID 15302865 DOI: 10.1074/Jbc.M407368200 |
0.446 |
|
| 2004 |
Luo K. Ski and SnoN: negative regulators of TGF-beta signaling. Current Opinion in Genetics & Development. 14: 65-70. PMID 15108807 DOI: 10.1016/j.gde.2003.11.003 |
0.516 |
|
| 2004 |
Conery AR, Cao Y, Thompson EA, Townsend CM, Ko TC, Luo K. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nature Cell Biology. 6: 366-72. PMID 15104092 DOI: 10.1038/Ncb1117 |
0.824 |
|
| 2003 |
Luo K. Negative regulation of BMP signaling by the ski oncoprotein. The Journal of Bone and Joint Surgery. American Volume. 85: 39-43. PMID 12925608 |
0.436 |
|
| 2003 |
He J, Tegen SB, Krawitz AR, Martin GS, Luo K. The transforming activity of Ski and SnoN is dependent on their ability to repress the activity of Smad proteins. The Journal of Biological Chemistry. 278: 30540-7. PMID 12764135 DOI: 10.1074/Jbc.M304016200 |
0.578 |
|
| 2002 |
Wu JW, Krawitz AR, Chai J, Li W, Zhang F, Luo K, Shi Y. Structural mechanism of Smad4 recognition by the nuclear oncoprotein Ski: insights on Ski-mediated repression of TGF-beta signaling. Cell. 111: 357-67. PMID 12419246 DOI: 10.1016/S0092-8674(02)01006-1 |
0.454 |
|
| 2001 |
Yang Z, Zhu Q, Luo K, Zhou Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription Nature. 414: 317-322. PMID 11713532 DOI: 10.1038/35104575 |
0.343 |
|
| 2001 |
Stroschein SL, Bonni S, Wrana JL, Luo K. Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN. Genes & Development. 15: 2822-36. PMID 11691834 DOI: 10.1101/Gad.912901 |
0.831 |
|
| 2001 |
Bonni S, Wang HR, Causing CG, Kavsak P, Stroschein SL, Luo K, Wrana JL. TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nature Cell Biology. 3: 587-95. PMID 11389444 DOI: 10.1038/35078562 |
0.825 |
|
| 2000 |
Wang W, Mariani FV, Harland RM, Luo K. Ski represses bone morphogenic protein signaling in Xenopus and mammalian cells. Proceedings of the National Academy of Sciences of the United States of America. 97: 14394-9. PMID 11121043 DOI: 10.1073/pnas.97.26.14394 |
0.469 |
|
| 1999 |
Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science (New York, N.Y.). 286: 771-4. PMID 10531062 DOI: 10.1126/Science.286.5440.771 |
0.828 |
|
| 1999 |
Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S, Zhou Q. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes & Development. 13: 2196-206. PMID 10485843 DOI: 10.1101/Gad.13.17.2196 |
0.828 |
|
| 1999 |
Stroschein SL, Wang W, Luo K. Cooperative binding of Smad proteins to two adjacent DNA elements in the plasminogen activator inhibitor-1 promoter mediates transforming growth factor beta-induced smad-dependent transcriptional activation. The Journal of Biological Chemistry. 274: 9431-41. PMID 10092624 DOI: 10.1074/jbc.274.14.9431 |
0.807 |
|
| 1997 |
Luo K, Lodish HF. Positive and negative regulation of type II TGF-β receptor signal transduction by autophosphorylation on multiple serine residues Embo Journal. 16: 1970-1981. PMID 9155023 DOI: 10.1093/Emboj/16.8.1970 |
0.321 |
|
| 1996 |
Luo K, Lodish HF. Signaling by chimeric erythropoietin-TGF-β receptors: Homodimerization of the cytoplasmic domain of the type I TGF-β receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction Embo Journal. 15: 4485-4496. PMID 8887540 |
0.323 |
|
| Show low-probability matches. |